EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age

Wei Wu, Chunxiu Gong, Yuchuan Li, Yuhua Hu, Haihong Gong, Junfen Fu, Ke Huang, Pin Li, Xiaoping Luo

Hormone and Metabolic Research · 2023-09 · 55 (09) · 599-609

DOI: 10.1055/a-2136-8654 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hormone and Metabolic Research, online erschienen am 07.09.2023. Verfasst von Wei Wu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Hauptthemen laut MEDLINE: Human Growth Hormone. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a lack of long-term data on the benefit of growth hormone (GH) treatment in Chinese children born small for gestational age (SGA). This study was conducted to assess the long-term efficacy and safety of GH treatment in children born SGA. One hundred and twenty prepubertal SGA children who did not achieve catch-up growth with height remained less than –2 standard deviations (SD) below gender-specific height were enrolled in this two-year, randomized, dose-comparative study followed by an extension study of up to 10 years. Daily subcutaneous injections of 0.23 mg/kg/week [low-dose (LD) group] or 0.46 mg/kg/week [high-dose (HD) group] somatropin were given for 104 weeks. Dosing in the extension study was≤0.46 mg/kg/week. The main outcome measures were change in height SD score (ΔHT-SDS), height velocity, insulin-like growth factor (IGF)-1, and IGF-1/IGF binding protein-3 (IGFBP-3) molar ratio. ΔHT-SDS at week 104 was 0.91±0.53 and 1.52±0.64 in the LD and HD groups (intergroup p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Human Growth HormoneAdultMaleFemaleInfant, NewbornHumansChildInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IGestational AgeInfant, Small for Gestational Age

Substanzen

Human Growth HormoneInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor I

Autor:innen und Institutionen

  • Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Endocrine and Genetics and Metabolism, Beijing Children's Hospital, Beijing, China.
  • Pediatrics, Jiangsu Provincial People's Hospital, Jiangsu, China.
  • Endocrinology, Children's Hospital of Zhejiang University School of Medicine, National Clinical Research Center for Child Health, Hangzhou, China.
  • Medical Genetics and Endocrinology, Children's Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Children's Hospital, Shanghai, China.

Zitieren

APA

Wu, W., Gong, C., Li, Y., Hu, Y., Gong, H., Fu, J., Huang, K., Li, P., & Luo, X. (2023). Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age. Hormone and Metabolic Research, 55(09), 599-609. https://doi.org/10.1055/a-2136-8654

Vancouver

Wu W, Gong C, Li Y, Hu Y, Gong H, Fu J, et al. Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age. Hormone and Metabolic Research. 2023;55(09):599-609. doi:10.1055/a-2136-8654

BibTeX
@article{Wu2023,
  author = {Wu, Wei and Gong, Chunxiu and Li, Yuchuan and Hu, Yuhua and Gong, Haihong and Fu, Junfen and Huang, Ke and Li, Pin and Luo, Xiaoping},
  title = {Long-Term Efficacy and Safety of Recombinant Human Growth Hormone in Children Born Small for Gestational Age},
  journal = {Hormone and Metabolic Research},
  year = {2023},
  volume = {55},
  number = {09},
  pages = {599--609},
  doi = {10.1055/a-2136-8654}
}
Kostenlos starten →